Stock Analiz

Viridian Therapeutics, Inc.\DE (VRDN) stock forecast and price target

Price $30.87 · data as of November 13, 2026

12-month price target

Average target$42.19
Upside / downside+36.7%
Analysts16
ConsensusStrong buy
Low $33.00Average $42.19High $54.00

Gold marker: average target · white marker: today’s price ($30.87)

Analyst ratings

Strong buy 3Buy 14Hold 0Sell 0Strong sell 0

Earnings and revenue estimates

PeriodEPS estimateEPS growthRevenue estimate
Current fiscal year
ends December 31, 2026
$-3.51−5.6%$75M
Next fiscal year
ends December 31, 2027
$-2.13+39.2%$313M
Next quarter
ends December 31, 2026
$-0.74+31.7%$49M
Quarter after
ends March 31, 2027
$-0.75+16.9%$68M

Consensus of the analysts covering Viridian Therapeutics, Inc.\DE, updated daily. In the last 30 days 5 estimates were raised and 1 lowered.

Frequently asked questions

What is the Viridian Therapeutics, Inc.\DE stock price target?

The average 12-month target from 16 analysts is $42.19, 36.7% above the current price of $30.87 Targets range from $33.00 to $54.00.

Is Viridian Therapeutics, Inc.\DE a buy according to analysts?

The consensus rating is “Strong buy” (3 strong buy, 14 buy). Ratings are opinions, not guarantees; this is not investment advice.

How much is Viridian Therapeutics, Inc.\DE expected to earn?

Analysts expect EPS of $-3.51 for the fiscal year ending December 31, 2026 and $-2.13 the year after.

Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.